-
CUA 2024 | Dr. Jeremy Teoh: Addressing Unmet Needs in NMIBC and Exploring Advanced Diagnostic and Treatment Strategies
Bladder cancer is one of the most common malignant tumors among the Chinese population, with 75% of cases classified as non-muscle invasive bladder cancer (NMIBC), which has a high postoperative recurrence rate. What are the unmet diagnostic and treatment needs of NMIBC patients? Which research findings may change future clinical practice for NMIBC? During the…
-
ESMO 2024丨Dr. Fufu Zheng: Progress in Urologic Cancer Research and Explorations Likely to Change Clinical Practice for Advanced Renal Cancer
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting is being held from September 13-17 in Barcelona, Spain. Several key studies in the field of urologic cancers have attracted significant attention at the conference. Urology Frontier invited Dr. Fufu Zheng from the Department of Urology at The First Affiliated Hospital , Sun Yat-sen University…
-
Metabolic-Related Diseases in Autoimmune Hepatitis Patients Promote Liver Fibrosis
Study Overview: The study analyzed the clinical characteristics of 283 AIH patients who underwent liver biopsies at Ruijin Hospital between January 2016 and February 2022. Prevalence of MADs in AIH…
-
Dr. Yonghong Xiao: From Concept to Action, Implementing One Health Strategies and Multidisciplinary Cooperation | Chairperson Interview
01 Infectious Diseases Frontier: Congratulations on the successful conclusion of this conference. Compared to the first conference, what changes or innovations did this year’s event introduce in terms of content,…
-
Revolutionizing NSCLC Treatment: Dr. Baohui Han and Dr. Mitsudomi Unveil New Frontiers in Immunotherapy Strategies
The 27th National Clinical Oncology Conference and 2024 CSCO Academic Conference, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing CISCO Clinical Oncology Research Foundation, took place in Xiamen from September 25 to 29, 2024. During this event, Dr. Tetsuya Mitsudomi, who has led several large-scale immunotherapy clinical trials, gave an academic…
-
ESMO 2024 | Dr. Wei Yu: Advances in Perioperative Immunotherapy and Combined Immunotherapy for Muscle-Invasive Urothelial Carcinoma Patients
Research has shown that nearly 50% of patients with muscle-invasive urothelial carcinoma (MIUC) will experience recurrence with distant metastases. Therefore, exploring perioperative treatments for muscle-invasive bladder cancer (MIBC) is crucial to improving patient outcomes. The 2024 European Society for Medical Oncology (ESMO) Congress, held from September 13 to 17 in Barcelona, Spain, highlighted several advances…
-
Dr. Hua Wang: New Approaches in Marginal Zone Lymphoma Treatment – Rethinking Chemotherapy-Free and Combination Strategies丨The 5th Tianjin International Lymphoma Symposium
From September 6-8, 2024, the 5th Tianjin International Lymphoma Symposium was successfully held. The conference featured twelve specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform for promoting international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Hua Wang from the Sun Yat-sen University Cancer Center to review…
-
Mesenchymal Stem Cell-Derived Exosomes Alleviate Liver Fibrosis
Identification and Characterization of UC-MSCs and UC-MSCs-Exo The researchers isolated UC-MSCs from human umbilical cord tissue. These cells were spindle-shaped, adherent, and capable of differentiating into adipocytes, osteoblasts, and chondrocytes.…
Connecting Medical Expertise through Media